For instance, BCR-ABL kinase inhibitors are used for chronic myeloid leukemia and EGFR tyrosine kinase inhibitors are used for NSCLC with EGFR mutations. This evidence concerns the gene EGFR and chronic myelogenous leukemia, BCR-ABL1 positive.